Seeking Alpha: AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development
AGC Biologics Partners with ATUM to Accelerate Timelines for Cell Line Development
KXAN: Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development
Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development
AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM for integrating the Leap-In transposase expression platform into its services. With this ...
The Victoria Advocate: Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development | | victoriaadvocate.com
Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development | | victoriaadvocate.com
Longview News-Journal: Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development | | news-journal.com
Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology to Accelerate & De-Risk Cell Line Development | | news-journal.com
New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...
A biotech company pioneering transposases for cell line engineering claims to have widened the applications of these tools. Oren Beske, PhD, gave a talk at BioProcess International, about how ATUM is ...
BioProcess International: De‑Risking Biologics Development: Practical Strategies to Move Faster from Cell Line to Clinic
De‑Risking Biologics Development: Practical Strategies to Move Faster from Cell Line to Clinic